Vivos Therapeutics (NASDAQ:VVOS – Get Free Report) and CVRx (NASDAQ:CVRX – Get Free Report) are both small-cap medical companies, but which is the better investment? We will compare the two companies based on the strength of their institutional ownership, analyst recommendations, valuation, profitability, risk, dividends and earnings.
Profitability
This table compares Vivos Therapeutics and CVRx’s net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Vivos Therapeutics | -86.19% | -335.04% | -93.58% |
| CVRx | -116.91% | -93.06% | -51.78% |
Analyst Ratings
This is a summary of recent recommendations for Vivos Therapeutics and CVRx, as provided by MarketBeat.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Vivos Therapeutics | 0 | 0 | 2 | 0 | 3.00 |
| CVRx | 0 | 1 | 6 | 0 | 2.86 |
Volatility & Risk
Vivos Therapeutics has a beta of 7.47, indicating that its share price is 647% more volatile than the S&P 500. Comparatively, CVRx has a beta of 1.34, indicating that its share price is 34% more volatile than the S&P 500.
Earnings & Valuation
This table compares Vivos Therapeutics and CVRx”s top-line revenue, earnings per share and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Vivos Therapeutics | $14.58 million | 1.49 | -$13.58 million | ($5.68) | -0.65 |
| CVRx | $51.29 million | 5.87 | -$59.97 million | ($2.69) | -4.30 |
Vivos Therapeutics has higher earnings, but lower revenue than CVRx. CVRx is trading at a lower price-to-earnings ratio than Vivos Therapeutics, indicating that it is currently the more affordable of the two stocks.
Insider and Institutional Ownership
26.4% of Vivos Therapeutics shares are owned by institutional investors. Comparatively, 75.3% of CVRx shares are owned by institutional investors. 3.0% of Vivos Therapeutics shares are owned by insiders. Comparatively, 18.9% of CVRx shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.
Summary
CVRx beats Vivos Therapeutics on 8 of the 14 factors compared between the two stocks.
About Vivos Therapeutics
Vivos Therapeutics, Inc., a medical technology company, develops and commercializes treatment modalities for patients with dentofacial abnormalities, obstructive sleep apnea (OSA), and snoring in adults. It offers The Vivos Method, a non-invasive, non-surgical, non-pharmaceutical, multi-disciplinary treatment modality for the treatment of dentofacial abnormalities, OSA, and snoring. The company also offers VivoScore Program, a screening and home sleep test in adults and children. It markets and sells its appliances, and related treatments and services to licensed professionals, primarily general dentists in the United States and Canada. Vivos Therapeutics, Inc. was founded in 2016 and is based in Littleton, Colorado.
About CVRx
CVRx, Inc., a commercial-stage medical device company, focuses on developing, manufacturing, and commercializing neuromodulation solutions for patients with cardiovascular diseases. The company offers Barostim, a neuromodulation device indicated to improve symptoms for patients with heart failure with reduced ejection fraction or systolic heart failure. It sells its products through direct sales force, as well as sales agents and independent distributors in the United States, Germany, and internationally. The company was incorporated in 2000 and is headquartered in Minneapolis, Minnesota.
Receive News & Ratings for Vivos Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Vivos Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
